Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: Data from KIMS (Pfizer International Metabolic Database)

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4449-4454

  Popovic, Vera ^a   Mattsson, Anders F ^b   Gaillard, Rolf C ^c   Wilton, Patrick ^b   Kołtowska Häggström, Maria ^b   Ranke, Michael B ^d  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b PFIZER INC   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BODY MASS; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENDER; GROUPS BY AGE; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LOGLINEAR MODEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; TREATMENT DURATION; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; DRUG INDUSTRY; FACTUAL DATABASE; HYPOPITUITARISM; INTERNATIONAL COOPERATION; MIDDLE AGED; NEOPLASMS; RISK;

ADULT; AGED; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG INDUSTRY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; NEOPLASMS; RISK;

EID: 77956569406     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0287     Document Type: Article

References (24)

1. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
2. Grimberg A, Cohen P 2000 Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9 (Pubitemid 30130219)
3. Samani AA, Yakar S, LeRoith D, Brodt P 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47 (Pubitemid 46220849)
4. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B 2007 The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113 (Pubitemid 350134889)
5. Pollak MN, Schernhammer ES, Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518
6. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
7. Holly J, Perks C 2006 Growth hormone and cancer: are we asking the right questions? Clin Endocrinol (Oxf) 64:122-124
8. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic, Marinkovic J 1998 Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 49:441-445
9. Stochholm K, Gravholt CH, Laursen T, Laurberg P, Andersen M, Kristensen LØ, Feldt-Rasmussen U, Christiansen JS, Frydenberg M, Green A 2007 Mortality and GH deficiency: a nationwide study. Eur J Endocrinol 157:9-18
10. Svensson J, Bengtsson BA, Rosén T, Odén A, Johannsson G 2004 Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306-3312 (Pubitemid 38960692)
11. Swerdlow AJ, Higgins CD, Adlard P, Preece MA 2002 Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360:273-277
12. Freedman RJ, Malkovska V, LeRoith D, Collins MT 2005 Hodgkin lymphoma in temporal association with growth hormone replacement. Endocr J 52:571-575 (Pubitemid 41609046)
13. Monson JP 2003 Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 148 (Suppl 2):S9-S14 (Pubitemid 36531482)
14. Riis P 2003 Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev Bioeth 1:15-25
15. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A 2008 Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 17:90-102 (Pubitemid 351187389)
16. Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthén L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P, German KIMS Board 2003 Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60:53-60.
17. Mattsson A, Svensson D, Schuett B, Osterziel KJ, Ranke MB 2008 Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Horm IGF Res 18:506-516
18. Spiegelman D, Hertzmark E 2005 Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 162:199-200 (Pubitemid 41373523)
19. Jørgensen JO, Blum WF, Horn N, Møller N, Møller J, Ranke MB, Christiansen JS 1993 Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients. Acta Endocrinol (Copenh) 128:513-520
20. Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, Jørgensen JO, Cuneo RC, Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L, Baxter RC, Basset EE, Sönksen PH 2000 The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab 85:4193-4200
21. Russo VC, Schütt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB, Bach LA, Werther GA 2005 Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445-4455 (Pubitemid 41324043)
22. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C, Stalsberg H 2005 Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58:361-366 (Pubitemid 40516165)
23. Jogie-Brahim S, Feldman D, Oh Y 2009 Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 30:417-437
24. Li L, Huang X, Huo K 2010 IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep 37:127-140